Journal of diabetes
-
Journal of diabetes · Sep 2013
HbA1c and the diagnosis of diabetes and prediabetes in a middle-aged and elderly Han population from northwest China (HbA1c).
To identify the optimal threshold of HbA1c and to evaluate the predictive performance of HbA1c levels in diagnosing diabetes and prediabetes in a middle-aged and elderly Han Chinese population from northwest China. ⋯ HbA1c is an effective and convenient method for diagnosing diabetes and prediabetes. HbA1c thresholds of 6.4% and 6.1% may be used as diagnostic criteria for diabetes and prediabetes, respectively, in the Han Chinese population living in northwest China.
-
Journal of diabetes · Mar 2013
Dietary supplementation with Ipomoea aquatica (whole leaf powder) attenuates maternal and fetal oxidative stress in streptozotocin-diabetic rats.
The rate of congenital anomalies, as well as morbidity and mortality of both the mother and fetus, is increased in diabetic pregnancy. Oxidative stress (OS) has been implicated in these effects because of the beneficial effects of several antioxidants in diabetic embryopathy. In the present study, we assessed attenuation of maternal and fetal OS and diabetic embryopathy by Ipomoea aquatica Forsk. (Convolvulaceae). ⋯ The data suggest that IA supplementation during pregnancy provides considerable protection against diabetes-induced OS in the mother and fetus. Thus, I. aquatica may be an effective therapeutic supplement.
-
Journal of diabetes · Mar 2013
Randomized Controlled TrialEfficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes.
New therapeutic approaches are needed to improve glycemic control in patients with type 2 diabetes (T2D), a progressive disorder that often requires combination therapy. The present study assessed the efficacy and safety of sitagliptin as add-on therapy to metformin and rosiglitazone in patients with T2D. ⋯ In patients with T2D, the addition of sitagliptin for 54 weeks to ongoing therapy with metformin and rosiglitazone improved glycemic control and was generally well tolerated compared with placebo.
-
Journal of diabetes · Sep 2012
Randomized Controlled Trial Multicenter StudyThe addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes.
The present study was conducted to evaluate the efficacy, safety and tolerability of sitagliptin added to ongoing metformin therapy in Chinese patients with type 2 diabetes (T2DM) who failed to achieve adequate glycemic control with metformin monotherapy. ⋯ The addition of sitagliptin 100 mg to ongoing metformin therapy significantly improved glycemic control and was generally well tolerated in Chinese patients with T2DM who had inadequate glycemic control on metformin alone.